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Abstract
Novel coronavirus (SARS-CoV-2) out-broke in the city of Wuhan in China 
and widely spread across the globe in a pandemic manner, causing societal and 
economic disruptions. Though the origin of the novel virus is still a debating topic, 
it is certain that SARS-CoV-2 acquired human to human transmission capacity. 
Regardless of aggressive containment and quarantine approaches, the number of 
confirmed cases continues to rise and being reported due to its highly infectious 
nature. As of the time, there is a little scope for the antiviral drugs or vaccines for 
the treatment of coronavirus infection; due to the vigorous mutation rate in the 
viral genome. However, existing anti-parasite drugs like ivermectin and chloro-
quine could effectively inhibit the virus has been reported. Few of the vaccines have 
come up with certain degree of efficacy and many are under the clinical trial phase. 
The research on novel coronavirus is still in the preliminary stage. In this chapter, 
we systematically summarize the origin, transmission route, molecular character-
ization, pathogenic mechanism, contagious nature, clinical symptoms, diagnosis, 
treatment, mutation and infection as well as prevention strategy of coronavirus 
disease based on the recently available literature. In addition to this, this chapter 
presents updated insights of the current state of knowledge pertaining to novel 
coronavirus and can be referred for potential future studies.
Keywords: Novel coronavirus (SARS-CoV-2), coronavirus disease, prevention 
strategy, transmission capacity, drug targets, treatment methods, virus structure, 
mutation
1. Introduction
In December 2019, Wuhan city in China became the center of origin of the 
novel coronavirus disease with the acronym COVID-19 outbreak that continues 
to spread quickly across the globe in a very short time. Due to its severe infection 
rate, on January 30, 2020, World Health Organization (WHO) declared COVID-
19 as the public health emergency of international concern (PHEIC), followed 
by a worldwide pandemic declaration on March 11, 2020. As of May 5, 2020, it 
has spread to 220 countries with 3665403 confirmed covid-19 positive cases. The 
recent data (as of June 28, 2021) show that the number of countries affected by 
Covid-19 is 229, with a total of 181,741,361 confirmed cases of COVID-19 and 
3,936,510 deaths. It is anticipated that the full extent of spreading and severity 
of this 2019 novel coronavirus is yet to be seen and global control of COVID-19 
will be one of the toughest challenges humanity has ever faced [1, 2]. According 
to the international committee on taxonomy of viruses (ICTV) classifications, 
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coronaviruses belong to the order Nidovirales, family Coronaviridae, and sub-family 
Coronavirinae, as shown in Figure 1. These are the largest group of viruses belong-
ing to the Nidovirales order. The sub-family Coronavirinae is further divided into 
four genera, such as Alphacoronavirus, Betacoronavirus, Gammacoronavirus, and 
Deltacoronaviruswithfour different lineages (A (embecovirus), B (sarbecovirus), C 
(merbecovirus), and D (nobecovirus)) of the Betacoronavirusgenus [3, 4]. COVID-19, 
officially named by the WHO on February 11, 2020, is caused by the severe acute 
respiratory syndrome coronavirus 2 (named by ICTV), otherwise known as SARS-
CoV-2. The emerging SARS-CoV-2 is a beta coronavirus of lineage B and seems to 
be the seventh member of the coronaviruses that infect humans, primarily targeting 
the respiratory system [5]. The first human coronavirus (HCoV), named B814, was 
isolated in 1965 from patients with common cold [6]. The other six different HCoVs 
include severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East 
respiratory syndrome coronavirus (MERS-CoV), HCoV- 229E, HCoV-OC43, 
HCoV-NL63, and HCoV-HKU1. Among these HCoVs, HCoV-NL63 and HCoV-
229E belong to Alphacoronavirus, HCoV-HKU1 and HCoV-OC43 belong to lineage 
A, SARS-CoV to lineage B, and MERS-CoV to lineage C of the Betacoronavirusas 
depicted in Figure 1.
HCoVs are zoonotic pathogens that originated in animals and all HCoVs are 
believed to have a bat origin, with the exception of Betacoronavirus lineage A that 
Figure 1. 
Classification of novel corona virus.
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may have rodent origin [7, 8]. Similar to the case of other SARS-CoVs, the bat might 
be the probable origin for SARS-CoV-2 as SARS-CoV-2 shares about 96% whole-
genome sequence similarity with the bat coronavirus (BatCoV). The confirmed and 
suspected origins of HCoVs are summarized in Figure 2.
Zhou et al. (2020), through complete genome analysis of samples collected from 
COVID-19 patients, found that SARS-CoV-2 is a Betacoronavirus with a sequence 
identity of 96% with a bat coronavirus [9]. Studies of Pasteur Institute, Shanghai 
also highlighted that the natural hosts of SARS-CoV-2 might be the bats [10]. 
However, few studies also highlighted that the pangolin is expected as an intermedi-
ate host of the SARS-CoV-2 [11, 12]. Zhang et al. (2019) reported that coronavirus 
from the pangolin might be the origin of the SARS-CoV-2 on the basis of genome 
sequence identity [11]. However, the claim was rejected by Cyranoski (2020), 
based on the fact that the origin is not by the genomic sequence similarity but by 
the receptor-binding domain (RBD) of the virus that enables the virus to enter the 
host cell [13]. Although, the potential natural and intermediate host of the virus is 
not fully established, regardless of its initial transmission source, it is certain that 
SARS-CoV-2 acquired the capacity for human to human transmission [14]. SARS-
CoV-2 is highly infectious; the entire population is generally highly susceptible to 
infection, and respiratory droplets through coughing and sneezing of COVID-19 
patients and coming into contact with them are the primary infectious source in the 
population. It is even claimed by some experts that transmission during conversa-
tions through micro-droplet may possibly be the third infection route. The digestive 
tract can also be a potential route of infection as SARS-CoV-2 is detected in the stool 
and gastro-intestinal tract of COVID-19 patients, in addition to its detection in 
saliva, tear, urine, etc. [15, 16]. There was no evidence of transmission from mother 
to child during pregnancy [17]. Though based on the currently available evidence, 
bats are considered to be the natural hosts and pangolins are the intermediate hosts, 
the origin of SARS-CoV-2 necessitates further in-depth investigations.
Figure 2. 
Probable origin and intermediate host during interspecies transmission of the corona virus.
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2. Molecular characterization and pathogenic mechanism
Coronaviruses are enveloped, spherical, or exhibit size and shape variation 
(pleomorphic) with a diameter in the range of 60–140 nm containing a positive 
sense, single-stranded RNA genome of approximately 26–32 kilobase size, the larg-
est genome among RNA viruses [8, 18]. The genomic RNA contains multiple open 
reading frames (ORFs) for encoding 16 non-structural proteins (nsps) and four 
structural proteins like spike (S), envelope (E), membrane (M), and nucleocapsid 
(N). About two-thirds of genomic RNA is located in the first ORF (ORF1a/b) 
that helps in the translation of two polyproteins viz. pp1a and pp1ab at the 5′ end. 
Further, the subsequent proteolytic cleavages of polyproteins generate 16 non-
structural proteins (NSP). The remaining part of the virus genome encodes the four 
important structural proteins, E, S, N, and M, including other accessory proteins 
that interfere with the host’s innate immune response [19, 20]. The invariant gene 
order is 5’-ORF1a-ORF1b-S-E-M-N-3′, with additional small ORFs in between the 
structural genes for encoding accessory proteins. The term ‘corona’ in Latin means 
‘crown’ under the electron microscope observation; the spike protein projections of 
the virus appear as a crown, hence termed as ‘coronavirus’ (Figure 3a).
3. Infection strategy
2019-nCoV is extremely contagious and with very high transmission capacity, 
the virus is transmitted from person to person with ease. The transmission capacity 
is represented based on the reproduction number symbolized as R0 that signifies the 
average number of secondary cases (infectee) caused by the primary case (infector) 
in a population highly susceptible to infection [21]. The value R0 > 1 indicates the 
rapid spreading of the infection whereas R0 < 1 signifies the low extension capac-
ity of the infectious disease. The R0 value of COVID-19 is in the range of 1.4–2.5, 
whereas severe acute respiratory syndrome coronavirus (SARS-CoV) is 0.67–1.23 
and Middle East respiratory syndrome coronavirus (MERS-CoV) is 0.29–0.8; there-
fore, COVID-19 could be more easily transmitted [22, 23]. However, there are cases 
when an infected individual will not transmit the disease to anyone or can infect far 
more people than the standard transmission rate and the individuals are termed as 
“super-spreaders” [22]. In COVID-19, for the first time in early 2020, two patients 
were reported to be super-spreaders. One was a British national who had infected a 
dozen others whereas another suspect, a South Korean woman, had infected several 
dozens of others. The rate of initial spread is also dependent on the serial interval, 
which means the time gap between the onset of illness in an infector and in an 
infectee. The serial interval can be estimated by linking dates of onset of illness for 
infector-infectee pairs. The serial interval for COVID-19 is 4.4–7.5 days, whereas the 
mean value for SARS-CoV was 8.4 days, indicating the rapid transmission nature of 
COVID-19 [24].
It is reported in the literature that SARS-CoV-2 uses angiotensin converting 
enzyme 2 (ACE2) as its cell surface receptor and the binding of the S protein to the 
ACE2 receptor is the first step of viral infection followed by fusion with the cell 
membrane and subsequent viral entry to the respiratory mucosa [3, 18, 25]. As dem-
onstrated in Figure 3b, after entry and un-coating, the translation of ORFs from 
the viral genomic RNA occurs for encoding non-structural proteins. Subsequently, 
the nsps assemble into the replicase-transcriptase complex (RTC) to facilitate RNA 
replication and transcription. First of all, full-length negative-sense anti-genome is 
synthesized using the genomic RNA as a template, and subsequently, the negative-
sense strand serves as a template for the synthesis of new genomic and sub-genomic 
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RNA. Sub-genomic RNAs serve as mRNAs for the translation of structural proteins. 
The structural proteins and viral genomic RNA assemble in the endoplasmic reticu-
lum (ER) - Golgi intermediate compartment (ERGIC) mediated by M protein to 
form the mature virions. Ultimately, the virions are transported to the cell surface 
through smooth-wall vesicles and released by exocytosis for subsequent rounds of 
infection [3, 25].
4. Clinical symptoms
SARS-CoV-2 attacks the lower airway as the primary target of infection, causing 
a respiratory and systemic illness that subsequently progresses to a severe form of 
pneumonia in 10–15% of patients [26, 27]. Clinical symptoms of COVID-19 vary from 
asymptomatic state to critical illness, with acute respiratory distress (ARDS), acute 
cardiac injury, multi-organ failure (MOF) and at the end, development of small blood 
clots throughout the bloodstream (intravascular coagulopathy) [17, 28]. The symp-
toms of COVID-19 illness are cough, fever, fatigue, headache, muscle pain (myalgia), 
Figure 3. 
(a) Basic structure of Covid-19, (b) life cycle in the host.
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difficulty in breathing (dyspnoea), decreased lymphocytes in blood (lymphocytope-
nia), lower platelet count (thrombocytopenia), etc., which are indifferent from other 
respiratory infections [29]. However, the unique clinical symptoms of COVID-19 are 
runny nose (rhinorrhea), sneezing, sore throat, presence of infiltrate in the upper lobe 
of the lung that causes shortness of breath and subsequent decreased level of oxygen 
in the blood (hypoxemia), detection of viral RNA in samples of plasma, serum, whole 
blood, etc., (RNAemia) and sometimes gastrointestinal symptoms like diarrhea [29]. 
The incubation period of the virus is usually between 3 to 7 days on average, however 
with 1 day as the shortest and 14 days longest is observed in some circumstances. The 
symptoms of infection appear after the average incubation period of 5 days approxi-
mately however, the average time from onset of symptom to dyspnoea is five days, 
ARDS is eight days, and death is 6 to 41 days with a median of 14 days [18, 29, 30]. 
These periods are variable and dependent on several parameters like age and immu-
nity of the patient, typically shorter periods are observed for patients above 70 years 
old [30].
5. Diagnosis and treatment
As discussed in the previous section, based on the preliminary clinical features 
such as fever, sore throat, and dry cough of a suspected COVID-19 infectee can be 
investigated to confirm the exposure history of the person. In some of the cases, 
this may be asymptotic, i.e., showing none of the above mentioned clinical symp-
toms, hence, in those cases, the detection of viral genomic material is considered 
as the only reliable source of COVID-19 diagnosis. The method includes taking 
the samples from the (suspected) infectee in the form of nasopharyngeal swab, 
sputum, bronchoalveolar washing, endotracheal aspirates, followed by RNA extrac-
tion and subsequent analysis by reverse transcription polymerase chain reaction 
(RT-PCR) for synthesis, amplification, and identification of viral nucleic acid [18, 
25]. Since RT-PCR based techniques take a relatively longer time, therefore, the 
development of rapid diagnosis kits is on works. Clustered regularly interspaced 
short palindromic repeats (CRISPR) based diagnostics are such techniques believed 
in delivering the results within an hour without the need for sophisticated labora-
tory equipment. Based on this technology, SHERLOCK and DETECTR are two test 
methods developed by Sherlock Biosciences, and Mammoth Biosciences, respec-
tively and waiting for clinical verifications and approvals [31]. Another sophisti-
cated approach would be a serological assay in which the antibodies from the blood 
sample of the patients are analyzed to detect viral infections. Computed tomogra-
phy (CT) imaging is also a highly specific and sensitive method and a chest CT scan 
of the patients generally shows ground-glass opacities and infiltrates [17, 18].
As of the time, there are no specific, effective and proven antiviral drugs (and/
or) vaccines for the treatment of COVID-19 infection, so treatments are limited to 
support and palliative care only. The first-line treatment emphasizes maintaining 
hydration and controlling fever and cough through routine dosages of antipyret-
ics and expectorants [32]. Patients with severe respiratory distress should be 
administered with supplemental oxygen. The alternative treatment is based on 
the use of broad-spectrum antiviral drugs like neurominidase inhibitor (oselta-
mivir), nucleotide analogues (remdesivir), nucleoside analogues (ganciclovir), 
HIV-protease inhibitors (lopinavir, ritonavir) that can reduce the virus infection 
[33, 34]. As per a recent report by Chen et al. (2020), the effective dosage for the 
treatment of COVID-19 patients includes oral administration of 75 mg oseltamivir, 
500 mg lopinavir, 500 mg ritonavir twice a day and the intravenous administration 
of 0·25 g ganciclovir for 3–14 days [35]. Also, it is reported by many researchers that 
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the antimalarial-drug chloroquine could effectively inhibit the virus by virtue of its 
immune-modulating activity [36, 37]. Deng et al. (2020) confirmed the antiviral 
activity of Arbidol (small indole derivative molecule) on COVID-19 patients and 
the antiviral activity against SARS-CoV and also it blocks the viral fusion against 
the influenza A and B viruses and hepatitis C viruses [10, 38]. A clinical candidate, 
EIDD-2801, with high therapeutic potential against the influenza virus, is in devel-
opment, which can be a promising drug to be considered for the COVID-19 [39].
In addition to this, the synthetic recombinant interferons could be used for the 
treatment of COVID-19 based on their effectiveness against SARS-CoVs and MERS-
CoVs [10]. It is also discussed that a small recommended amount of vitamin C 
supplementation could effectively prevent COVID-19. Convalescent plasma therapy 
in which plasma of patients recovered from COVID-19 enriched with virus neutral-
izing antibodies is administered in a prophylactic manner to prevent infection in 
high-risk cases could also be an effective approach to alleviate COVID-19 infection. 
On 31st March 2020, the first US patient received convalescent plasma therapy for 
the COVID-19 treatment [40]. In the latest development, Caly et al. (2020) reported 
that Ivermectin existing anti-parasite inhibited SARS-CoV-2 and a single treatment, 
reduced approximately 5000 fold viral RNA in 48 h in in-vitro [41]. However, the 
anti-parasitic drug is not approved by U.S Food and Drug Administration (FDA) 
due to lack of well-designed clinical trials. It is also recommended that the existing 
related vaccines for RNA virus including encephalitis B and influenza, etc., could 
be explored as possible alternatives until the development of an effective COVID-19 
vaccine. There is an urgent need to establish a nonhuman animal model for a better 
understanding of the virus-host interactions and subsequent testing of potential 
drug/vaccines for COVID-19 infections [17].
6. Preventive measures to control the spread of the infection
Since there is limited availability of effective treatment for COVID-19, therefore, 
currently, prevention is used as a vital step in controlling the (community) spread of 
the infection. However, some unique features of the disease like a transmission from 
asymptomatic people, long incubation period, and infectivity in the incubation 
period even before the onset of symptoms, prolonged illness, and transmission after 
recovery, etc., make the preventive measures really more challenging [18]. First 
of all, extensive measures should be taken to limit human to human transmission 
with an emphasis on susceptible populations like healthcare providers and older 
people to prevent further transmission amplification and spread [42]. The second 
essential step must be the facilitation of advanced health surveillance systems along 
with rapid diagnostic facilities for the identification of cases. It should be followed 
by quarantine or isolation when necessary, with intensive care for patients and 
contact tracing for preventing further transmission by contacts who are infected 
[43]. Patients should be isolated in well ventilated room with regular decontamina-
tion, and they should follow cough and sneeze hygiene, practice hand hygiene and 
should be asked to wear surgical masks to prevent infection spreading. The health-
care workers attending the patients should be advised to use personal protective 
equipment (PPE) like gloves, N95 masks, goggles, protective suits, etc. The use of 
masks by healthy people though not recommended by WHO, owing to the recent 
finding by Japanese scientists that simple conversations in close proximity without 
coughs and sneeze could spread the virus through micro-droplets, it is advisable to 
wear masks, particularly in crowded public places [44]. Owing to the community 
spread nature of the virus, the government’s action to ban mass gatherings is an 
important preventive step and locking down cities, states, provinces as part of 
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the action plan of many governments, including India, the US, European Union, 
etc., will definitely be beneficial in flattening the pandemic. Physical contact with 
inanimate objects should be avoided since coronaviruses can remain infectious on 
these surfaces for up to 9 days, however, surface decontamination with ethanol (> 
70%) or 0.1% sodium hypochlorite can significantly reduce the virus infectivity 
even within 1 min exposure time [45]. The public should avoid non-essential travel 
to places with ongoing transmission and the countries should strictly implement 
preventive measures like travel screenings and quarantining of the travelers to con-
trol further spread of the infection. In countries with resource limitations, to triage 
a large number of cases, the proposed simple screening algorithm by Ayebare et al. 
(2020), as shown in Figure 4 can be followed for effective infection prevention and 
control [46].
International collaborations and co-operations are highly essential to minimize 
social as well as economic disruptions [43]. The government’s strategy for timely 
education and training of hospital staff and health care providers along with 
awareness and counseling to the general public about the risks of COVID-19 are 
absolutely necessary for minimizing the spread of the infection and managing an 
economic downturn. However, during this crisis, personal rather than government 
Figure 4. 
Outline of infection prevention and control (IPC) strategies.
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action might be most important and individual behavior will definitely play a cru-
cial role in infection prevention and control the spread of COVID-19. To date some 
of the countries have approved many anti-viral drugs as pharmacological treatment 
strategies for COVID-19. However, some approved COVID-19-specific vaccines are 
available (Table 1). Several companies have developed various vaccine candidates 
for human CoV infections which are in the clinical trial stage [47].
7. Future challenges in controlling the global pandemic
From the end of July 2020, an increase in new cases of SARS-CoV-2 infec-
tions was appeared in the different geographical territories of the European 
Union, confirmed about the origin of the second wave of outbreaks of these 
infectious diseases. On September 20, a new variant type of SARS-CoV-2, 
called B117, was first time identified in the United Kingdom (UK). Also, In 
December 2020, an unexpected rise in reported COVID-19 cases was observed 
due to the emergence of a new variant of SARS-CoV-2 (B.1.351) in South 
Africa. However, it was observed that that B117 is far more transmissible with 
comparatively less fatality rate [48–51]. Hence, it is important to correlate the 
mutation of the virus as well as the degree of pathogenicity. The existence of 
S.No Trade name of the 
vaccine
Company and country Remark
1 Comirnaty German company BioNTech, American company 
Pfizer
RNA vaccine
2 Covishield Oxford–AstraZeneca COVID-19 vaccine viral vector 
vaccine
3 Sputnik V COVID-
19 vaccine








5 Johnson & Johnson 
COVID-19 vaccine




6 Moderna COVID-19 
vaccine
American company Moderna RNA vaccine
7 CoronaVac Chinese company Sinovac Biotech. inactivated virus 
vaccine
8 Covaxin Bharat Biotech, India inactivated virus 
vaccine
9 Convidecia Chinese company CanSino Biologics and the 
Beijing Institute of Biotechnology of the Academy 
of Military Medical Sciences.
viral vector 
vaccine
10 EpiVacCorona Russian State Research Center of Virology and 
Biotechnology VECTOR
peptide vaccine
11 RBD-Dimer Chinese company Anhui subunit vaccine









Showing developed vaccine details for Covid-19 infection.
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genetic diversity and specific mutations in the genome of SARS-CoV-2 and 
the virulence property has been investigated by Abdullahi, et al. In this work, 
they focused on the mutations of the non-structural proteins (NSPs) such as 
nsp 2 and nsp 3, Spike protein and RNA-dependent RNA polymerase (RdRp). 
The spike protein is the key determining factor for the evolution, virulence and 
transmission [52]. Similarly, the enhanced infection property and pathogenic-
ity in case of SARS-CoV-2 is related to mutation at S-protein receptor-binding 
domain, has been studied by Padhi and Tripathi [53]. To address the signifi-
cance of mutation to infection, Yao et al. conducted an experimental work 
by considering eleven numbers of SARS-CoV-2 viral isolates and observed 
that the mutations are directly related to the increase in viral load as well as a 
cytopathic effect [54]. Bakhshandeh et al., emphasized that the gradual accu-
mulation of the genomic mutation in SARS-CoV-2 are having a crucial role in 
genetic variability of the virus. This helps the virus to escape from the host cell 
immunity and converts the strain in to a drug resistance virus with more deadly 
behavior [55]. Another recent study has uncovered that the rate of infection 
of novel corona virus is not only due to the mutation of the viral genome but 
also associated with host genetics, the genetic and epigenetic variations of the 
human population. For example, the ACE2 gene variation might be the key 
genetic factor for SARS-CoV-2 infection that facilitates the virus entry into 
human cells [56].
Currently, several strategies are being followed, such as contact tracing of 
infected people, enforcing the social distancing, maintaining the quarantine, and 
restricted mobility of people and use of disinfectant for self-protection purpose. 
However, none of these methods have proved to be effective in controlling the 
global pandemic caused by COVID-19. Usually, there are three basic areas that is to 
be emphasized more for the best control of the global pandemic [57–64].
1. Mass vaccination of the people:
2. The government of each country should take the initiative for the mass vacci-
nation for all the people that may be the most effective way of control. How-
ever, it may be challenging as the country should cross the financial burden 
and human resources to develop the technology as well as the material for mass 
production of the vaccine. Also, international collaboration for the same may 
be fruitful. In addition to this, the possible long term efficacy and the side ef-
fects of the vaccine should be well-studied.Herd immunity
3. Several studies have proved that the COVID-19 infection leads to the produc-
tion of antibodies in the patient against the SARS-CoV-2. So, if a large group 
of the population will induce resistance for the virus in their immunosystem, 
then it is expected that the entire population may be protected gradually, called 
herd immunity. However, the establishment of herd immunity in the popula-
tion is determined by a large number of molecular and immunological factors. 
Also, frequent change in the viral genome may be another hurdle for acquiring 
herd immunity.Implementation of new technologies
In order to protect the human population and in the limited effective treatment 
strategy for COVID-19 infection, the implementation of new and effective 
online technologies in different sectors is desirable. These technologies will help 
the people in the timely response and control of epidemics in the areas of public 
training, education, medication, including digital surveillance systems, tele-
medicine, rapid identification and diagnosis devices, and prediction about the 
future infection.
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8. Conclusion
The global impact of coronavirus disease is one of the heightening concerns of 
the present time. Though at this stage, it is not possible to determine the precise 
source of the coronavirus, however, the bats are considered as their natural hosts 
based on the available sequence based phylogenetic study. Genomic analysis 
revealed the arrangement of gene order and ORF positions. The largest genome 
RNA of coronavirus might be the reason behind the intraspecies variability and 
interspecies transmission via mutations and recombination mediated flexible genome 
modifications. Therefore, future outbreaks of zoonotic viruses cannot be over-
looked. So, to avoid the future threat of zoonotic viral outbreaks, comprehensive 
measures should be planned alongside curbing this corona pandemic. In addition to 
this, the mutation acquired by the virus from time to time changes its pathogenicity 
is a concern. So a thorough study is essential to establish the relationship between 
the mutated forms of the virus with respect to the different geographical areas to 
predict the future genotypic pattern change of the virus. Further, in-depth inves-
tigations at individual protein levels of the virus are necessary to precisely predict 
the origin, to predict mutation mediated evolutionary selection pressure, and for 
a better understanding and development of the potential drug molecule binding 
efficacy.
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